Jonathan Brammer
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jonathan Brammer sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Jonathan Brammer: 3 sponsored US clinical trials, 2 recruiting.
Jonathan Brammer sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is T-cell Large Granular Lymphocyte Leukemia, with 2 trials.
Upper-quartile sponsor footprint
Jonathan Brammer sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
NCT07356245
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
NCT05592015
Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
NCT05141682
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
What is open in the Jonathan Brammer pipeline
2 recruiting of 3 indexed (67% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: T-cell Large Granular Lymphocyte Leukemia (2 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jonathan Brammer: open-pipeline peers nationwide
Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Jonathan Brammer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
Related
What to do with this Jonathan Brammer page
3 registered trials is a research-attention snapshot, not an endorsement of Jonathan Brammer or any single study.
- 2 of Jonathan Brammer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- T-cell Large Granular Lymphocyte Leukemia is the condition Jonathan Brammer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See T-cell Large Granular Lymphocyte Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jonathan Brammer pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.